Rose-Hulman Institute of Technology
Undergraduate Mathematics Conference
April 21-22, 2017

Conference Home
Short Courses
  Math Dept.
  Conf. Archives
  Undergrad. Journal

The 2017 Rose-Hulman Undergraduate Mathematics Conference is over. Planning for the 2018 conference is currently underway. Please visit the 2018 page to see what we have planned so far.

Welcome to the 2017 Rose-Hulman Undergraduate Mathematics Conference. Use the links on the left-hand side of the page to navigate through the site. This is our 34th consecutive conference, and we look forward to hosting you on the beautiful Rose-Hulman campus.

The vision for the Rose-Hulman Undergraduate Mathematics Conference is to provide a venue to highlight and celebrate the accomplishments and work of undergraduate mathematicians and statisticians. The conference is put on largely by undergraduates for undergraduates. The topics of the 2017 conference are big data, data science, statistics, and modeling, with particular attention paid to the intersection of these topics with the biological sciences. The official conference catchphrase is Exploring the Crossroads of Mathematics, Biology, and Medicine.

Registration Information:

Online Registration will open on February 1, 2017. For the first time in several years we need to institute a $10 registration fee for all participants. However, Sandia National Laboratories has graciously agreed to cover the registration fees for all participants that register prior to the early registration deadline of April 7, 2017. All registrations occuring after the registration deadline need to be done in person at the conference and will need to pay the $10 registration fee.

Invited Speakers:

Meg EhmSpeaker: Meg Ehm
Title: Use of Human Genetics in Drug Discovery & Development

Before the turn of the century, there was a belief that genetics would have an important impact on drug discovery and development. Many thought that the identification of genes responsible for disease would directly identify drug targets – genes that can be modulated to achieve a therapeutic effect. Genetics was also widely touted as a method to identify patients who would likely respond to medications or who were likely to experience adverse effects. Almost 20 years later, systematic review and analysis of genetic information and drug approvals have demonstrated the importance of genetics in early discovery and for drug safety but have tempered enthusiasm for its use in predicting drug efficacy. I will review these results and highlight emerging techniques that use genetic data in drug discovery and development.

Meg Ehm is a Director of Genetics at GlaxoSmithKline located in King of Prussia, Pennsylvania. She develops and manages external collaborations that bring together GSK with academic and industry groups to build innovative capabilities capitalizing on genetic data that will improve the next generation of medicines. Currently, she co-leads a pharmaceutical industry consortium focused on accelerating translational research with genetic evaluation of clinically important phenotypes using electronic health record data and genetics to improve pipeline portfolio decisions. She received her BS degree from Vanderbilt University in mathematics and computer science and MA and PhD from Rice University in statistics. She completed a brief post-doctoral position at North Carolina State University in 2001 where she remains an Adjunct Professor of Statistics. She is a native Hoosier and graduated from Terre Haute South High School.

Mark InlowSpeaker: Mark Inlow
Title: New Mathematical and Statistical Analyses of Alzheimer's Brain Atrophy

Alzheimer's Disease causes neuron death and tissue shrinkage throughout the brain. However some regions, especially the hippocampus, are more severely affected. Since it is believed deleterious changes begin well before symptoms occur it is important to detect these changes in the earliest stages of Alzheimer's. In this talk we discuss methods we recently developed to successfully detect and describe hippocampal shrinkage in subjects with early mild cognitive impairment.

Mark Inlow is currently a Lead Data Analyst with the American Institutes for Research (AIR) in Washington, DC. He is also a consultant for the IU School of Medicine where he helps develop neuroimaging genomics algorithms for investigating Alzheimer's Disease. Before joining AIR he was a professor of statistics for 14 years with appointments at Rose-Hulman, the IU School of Medicine, and the University of Arizona. Prior to earning his statistics Ph.D. from Texas A&M in 2001, he worked as a statistician for DuPont, Science Applications International, StataCorp, the Naval Health Research Center, and the Naval Personnel Research and Development Center. A native Hoosier, Mark lives in Terre Haute with his wife Jen and their cat Marshmellow.


Eric Reyes
Joe Eichholz
Sylvia Carlisle
Joshua Holden
Key Dates

Registration Opens: February 1
Early Registration Ends: April 7
Abstract Submission Deadline: April 7
Online Registration Ends: April 17
Conference Dates: April 21-22, 2017
This conference is graciously sponsored by

Sandia National Labs Minitab